Stockreport

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Century Therapeutics, Inc.  (IPSC) 
PDF - Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical a [Read more]